Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

AUA symptom score value ≥9(9).
Signed informed consent.
Peak Urine flow rate <12 ml/sec on voided volume of >125mL.
...
AUA symptom score value ≥9(9).
Signed informed consent.
Peak Urine flow rate <12 ml/sec on voided volume of >125mL.
Diagnosed with symptomatic BPH.

Exclusion Criteria

PSA >10 ng/mL
Subject with bleeding disorder or liver dysfunction associated with a bleeding disorder.
Subject interested in future fertility/fathering children.
...
PSA >10 ng/mL
Subject with bleeding disorder or liver dysfunction associated with a bleeding disorder.
Subject interested in future fertility/fathering children.
Active urinary tract infection.
Compromised renal function (i.e., serum creatinine levels above 1.8 mg/dL).
Subjects whose pain response has been significantly decreased by any means (because the subject's ability to detect pain is a treatment safety mechanism).
Alpha blockers, antidepressants, androgens, within one week of treatment.
Subject with urethral stricture and/or bladder stones
Bladder antispasmodics (Ditropan or Detrol) within one week of treatment, unless there is documented evidence that the subject has been on the same drug dose for at least three months with a stable voiding pattern. The drug dose will not be altered or discontinued for the entrance into or throughout the study.
Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease.
Subject with the confirmed or suspected malignancy of the prostate
Subject with a history of any illness for which the Prolieve® treatment may pose additional risk to the subject.
Cardiac pacemaker or metallic implants or staples, etc. in the pelvic or femoral area.
Subject with a history of any illness or surgery that might confound the results of the study " or impede the successful completion of trial"
Subject with prostate weighing <20 or >80g.
5-alpha reductase inhibitors and gonadotropin releasing hormonal analog.
Subject with prostatic urethra length of <1.2 cm or >5.5 cm.
Residual bladder volume >250 mL measured by ultrasound.
Subject with neurogenic bladder and/or sphincter abnormalities due to Parkinson's, multiple sclerosis, cerebrovascular accident (CVA), diabetes, or other disease process.
Subject with the confirmed or suspected bladder cancer
Subject having large, obstructive middle lobe
Subject with full urinary retention.
Subject with previous pelvic irradiation or radial pelvic surgery
Subject with previous treatment to the prostate (e.g., surgery, balloon dilation, stents, laser, TUNA, or Indigo prostatectomy) and/or non-metallic urogenital implants (e.g., penile prostheses, artificial urinary sphincters)

Summary

Conditions
Benign Prostate Hyperplasia
Type
Interventional
Phase
Phase 4
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Only males

Inclusion Criteria

AUA symptom score value ≥9(9).
Signed informed consent.
Peak Urine flow rate <12 ml/sec on voided volume of >125mL.
...
AUA symptom score value ≥9(9).
Signed informed consent.
Peak Urine flow rate <12 ml/sec on voided volume of >125mL.
Diagnosed with symptomatic BPH.

Exclusion Criteria

PSA >10 ng/mL
Subject with bleeding disorder or liver dysfunction associated with a bleeding disorder.
Subject interested in future fertility/fathering children.
...
PSA >10 ng/mL
Subject with bleeding disorder or liver dysfunction associated with a bleeding disorder.
Subject interested in future fertility/fathering children.
Active urinary tract infection.
Compromised renal function (i.e., serum creatinine levels above 1.8 mg/dL).
Subjects whose pain response has been significantly decreased by any means (because the subject's ability to detect pain is a treatment safety mechanism).
Alpha blockers, antidepressants, androgens, within one week of treatment.
Subject with urethral stricture and/or bladder stones
Bladder antispasmodics (Ditropan or Detrol) within one week of treatment, unless there is documented evidence that the subject has been on the same drug dose for at least three months with a stable voiding pattern. The drug dose will not be altered or discontinued for the entrance into or throughout the study.
Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease.
Subject with the confirmed or suspected malignancy of the prostate
Subject with a history of any illness for which the Prolieve® treatment may pose additional risk to the subject.
Cardiac pacemaker or metallic implants or staples, etc. in the pelvic or femoral area.
Subject with a history of any illness or surgery that might confound the results of the study " or impede the successful completion of trial"
Subject with prostate weighing <20 or >80g.
5-alpha reductase inhibitors and gonadotropin releasing hormonal analog.
Subject with prostatic urethra length of <1.2 cm or >5.5 cm.
Residual bladder volume >250 mL measured by ultrasound.
Subject with neurogenic bladder and/or sphincter abnormalities due to Parkinson's, multiple sclerosis, cerebrovascular accident (CVA), diabetes, or other disease process.
Subject with the confirmed or suspected bladder cancer
Subject having large, obstructive middle lobe
Subject with full urinary retention.
Subject with previous pelvic irradiation or radial pelvic surgery
Subject with previous treatment to the prostate (e.g., surgery, balloon dilation, stents, laser, TUNA, or Indigo prostatectomy) and/or non-metallic urogenital implants (e.g., penile prostheses, artificial urinary sphincters)

Tracking Information

NCT #
NCT02021032
Collaborators
Not Provided
Investigators
Study Director: Perry Weiner, MD Jefferson Urology
About Us
Innovation
Privacy
Terms
Copyright
Get Well Soon © Copyright 2024